Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Uterine Carcinosarcoma: early-phase trial registry
2 of 4 indexed Uterine Carcinosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Uterine Carcinosarcoma: 4 US clinical trials tracked, 2 recruiting.
Uterine Carcinosarcoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Volastra Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition uterine-carcinosarcoma
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Uterine Carcinosarcoma lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Uterine Carcinosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Uterine Carcinosarcoma is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT07029399
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics
NCT05902988
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
Memorial Sloan Kettering Cancer Center
NCT05147558
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
Medical College of Wisconsin
NCT03694262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Uterine Carcinosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Uterine Carcinosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Uterine Carcinosarcoma page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Uterine Carcinosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Volastra Therapeutics sponsors the most Uterine Carcinosarcoma trials on record, review their full trial history before evaluating a specific study. See Volastra Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uterine Carcinosarcoma condition card totals 4 registered trials; most-linked intervention Rucaparib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.